Nurses from a range of departments at Fox Chase Cancer Center recently came together to put on a taco night for guests staying at the nearby AstraZeneca Hope Lodge of the American Cancer Society. Hope Lodge offers lodging at no cost for out-of-area cancer patients being treated in the Philadelphia area.
Fox Chase Cancer Center researchers have identified a way forward for personalized cancer treatments for a wide range of cancers. Their findings can provide new insight into the mechanisms of a small molecule and investigational new drug for cancer called ONC201. The drug not only stimulates a powerful anticancer protein called TRAIL, but also the death receptor for TRAIL (also known as DR5) on tumor cells. This allows TRAIL to specifically kill tumor cells.
Fox Chase Cancer Center encourages all individuals to start taking steps to reduce their risk for cancer. According to the American Cancer Society (ACS), more than one million Americans are diagnosed with cancer every year. Fortunately, people can help prevent cancer by making healthy lifestyle choices and getting regular recommended cancer screenings.
This month, we are highlighting a Phase 2 Clinical Trial for patients diagnosed with muscle invasive bladder cancer that will be led by Daniel M. Geynisman, MD, a medical oncologist at Fox Chase who specializes in genitourinary cancers.
A recent presentation at the American Society of Clinical Oncology (ASCO) meeting on Genitourinary Cancers discussed the role of DNA repair as a target in treatment of Metastatic castration-resistant prostate cancer (mCRPC).